diagnosis
Serum PSA should be measured and digital rectal examination (DRE) carried out in patients presenting with urinary symptoms. Prostate biopsy should be offered to men suspected to have a clinically significant prostate cancer, such as those with an abnormal DRE and elevated serum PSA. Prostate biopsy should be performed under transrectal ultrasound (TRUS) guidance, and a minimum of eight cores obtained. The extent of involvement of each core, and the Gleason score should be reported.
staging and risk assessment
General health and co-morbidities should be assessed. Clinical T stage should be evaluated by DRE. Pelvic imaging using MRI or CT should be performed before radical treatment when Partin tables indicate >15% risk of nodal involvement. Patients should be informed of the potential benefits and harms of the various options.
In the only randomized trial reported to date, radical prostatectomy improved overall survival at 10 years by 5% in comparison with watchful waiting (73% versus 68%, P = 0.04), but these results may not be generalizable to screen-detected cancers. In the only randomized trial to date, radical prostatectomy increased the rate of erectile dysfunction by 35% (80% versus 45%), and urinary leakage by 28% (49% versus 21%), in surgical centers. For low-risk disease (T1-2a, Gleason <6, PSA <10 mg/l), active surveillance with selected delayed intervention has given 99% disease-specific survival at 8 years. External beam radiotherapy should be delivered using conformal techniques, to a minimum target dose of 70 Gy given in 2.0 Gy fractions or the equivalent [II, B]. In nonrandomized prospective series brachytherapy with permanent implants results in similar long-term survival to radical prostatectomy with less chronic urinary symptoms and erectile dysfunction. Following radical prostatectomy patients should be monitored with a sensitive PSA assay, with salvage radiotherapy to the prostate bed given in the event of PSA failure.
locally advanced disease (T3-4 N0/X M0/X)
Long-term hormone therapy (androgen suppression or bicalutamide monotherapy) is a standard treatment. 
